At times dubbed a major disruptor in the biotech space, Moderna, Inc. (MRNA) saw its stock valuation soar throughout 2021. The COVID-19 vaccine producer’s mRNA technology was seen by investors as applicable to multiple illnesses, and the speculative buying pressure built up. Now, while shares have more or less come back to earth, some professionals have developed more neutral takes on the stock.   Denoting its successes, yet remaining subdued on its outlook, is Joseph Stringer of Needham & Co., who detailed Moderna’s robust pipeline, abundant purchase agreements for its vaccine, and potential for inorganic growth.
https://www.tipranks.com/news/article/moderna-may-need-a-booster-of-its-own?utm_source=advfn.com&utm_medium=referral